Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies
In search of an ideal partner or alternative to conventional immunosuppressive agents,
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant …
PURPOSE Hematopoietic cell transplantation (HCT) is curative for hematologic disorders,
but outcomes are historically inferior when using HLA-mismatched donors. Despite …
but outcomes are historically inferior when using HLA-mismatched donors. Despite …
[HTML][HTML] Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of …
B Dholaria, BN Savani, BK Hamilton, B Oran… - … and Cellular Therapy, 2021 - Elsevier
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …
Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in …
Abstract Purpose: Posttransplant cyclophosphamide (PTCy) is increasingly being utilized as
a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo …
a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo …
CD34+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using …
Previous observations have reported controversial conclusions regarding cell dose and
survival endpoints after allogeneic hematopoietic stem cell transplantation (HSCT). We …
survival endpoints after allogeneic hematopoietic stem cell transplantation (HSCT). We …
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
The ideal stem cell graft source remains unknown in haploidentical haematopietic cell
transplantation (haplo-HCT) with posttransplantation cyclophosphamide (PTCy). This study …
transplantation (haplo-HCT) with posttransplantation cyclophosphamide (PTCy). This study …
[HTML][HTML] Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical …
MP Pereira, M Remberger, C Chen, A Gerbitz… - … and Cellular Therapy, 2023 - Elsevier
The choice between an older matched sibling donor (MSD) and a younger matched
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …
Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV …
Z Huang, H Yan, Y Teng, W Shi, L Xia - Frontiers in Immunology, 2022 - frontiersin.org
Currently, the graft-versus-host disease (GVHD) prophylaxis consists of an
immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post …
immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post …
[HTML][HTML] Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide versus cyclosporine A and methotrexate in matched sibling donor …
Cyclosporine A (CSA) and methotrexate (MTX) is the standard graft-versus-host disease
(GVHD) prophylaxis regimen for matched sibling donor (MSD) allogeneic hematopoietic cell …
(GVHD) prophylaxis regimen for matched sibling donor (MSD) allogeneic hematopoietic cell …
Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical …
X Li, J Yang, Y Cai, C Huang, X Xu, H Qiu… - Frontiers in …, 2023 - frontiersin.org
Introduction The novel low-dose anti-thymocyte (ATG, 5 mg/kg) plus low-dose post-
transplant cyclophosphamide (PTCy, 50 mg/kg)(low-dose ATG/PTCy)-based regimen had …
transplant cyclophosphamide (PTCy, 50 mg/kg)(low-dose ATG/PTCy)-based regimen had …